IP Library Granted Patent US 10,226,456
Granted Patent B2
US 10,226,456 · App. 15/139,836 · Granted Mar 12, 2019

Methods and compositions for preventing opioid abuse

Inventor: John K. Thottathil (Mundelein, IL)
Assignee: 3ST Research LLC
A61K31/485A61K47/542C07D489/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,226,456
App. No.
15/139,836
Granted
Mar 12, 2019
Kind
B2
Abstract

Abuse-resistant opioid compounds, drug delivery systems, pharmaceutical compositions comprising an opioid covalently bound to a chemical moiety are provided. Methods of delivering an active ingredient to a subject and methods of preventing opioid abuse are also provided.

Claims (22)

1. An abuse-resistant opioid compound represented by Formula I:

O-X n .•T c   (I)

wherein,

O is an opioid selected from the group consisting of oxycodone and oxymorphone;

each X is an independent chemical moiety that is safe for human consumption having a hydrolyzable point of linkage to O though oxygen of an enol tautomer of O, such that hydrolysis releases activated opioid, and X consists of α-hydroxy acid;

T is a pharmaceutically acceptable salt;

c is from 0 to 5; and

n is from 1 to 10.

2. The abuse-resistant opioid compound of claim 1 , wherein X consists of lactic acid, mandelic acid, malic acid, or tartaric acid.

3. A pharmaceutical composition, comprising:

an abuse-resistant opioid compound; and

at least one pharmaceutical additive,

wherein the abuse-resistant opioid compound is represented by Formula I:

O-X n .•T c   (I)

wherein,

O is an opioid selected from the group consisting of oxycodone and oxymorphone;

each X is an independent chemical moiety that is safe for human consumption having a hydrolyzable point of linkage to O though oxygen of an enol tautomer of O such that hydrolysis releases activated opioid, and X consists of α-hydroxy acid;

T is a pharmaceutically acceptable salt;

c is from 0 to 5; and

n is from 1 to 10.

4. The pharmaceutical composition of claim 3 , wherein X consists of lactic acid, mandelic acid, malic acid, or tartaric acid.

5. The abuse-resistant opioid compound of claim 1 , wherein the abuse-resistant compound is selected from the group consisting of:

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2025
From: ALBANY MOLECULAR RESEARCH, INC.
To: CURIA BUFFALO R&D, LLC
Reel/Frame 073096/0798 →
SECOND LIEN INTELLECTUAL PROPERTY AGREEMENT SUPPLEMENT Recorded Jul 18, 2025
From: CURIA MISSOURI, INC.; CURIA GLOBAL, INC.; CURIA IP HOLDINGS, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 072050/0001 →
SECURITY INTEREST Recorded Jul 8, 2025
From: CURIA MISSOURI, INC.; CURIA GLOBAL, INC.; CURIA IP HOLDINGS, LLC
To: APOLLO ADMINISTRATIVE AGENCY, LLC
Reel/Frame 071629/0239 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2017
From: THOTTATHIL, JOHN K.
To: 3ST RESEARCH LLC
Reel/Frame 042969/0834 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2017
From: PELTIER, JAMES
To: THOTTATHIL, JOHN K.
Reel/Frame 042630/0617 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2017
From: WATERVILLE VALLEY TECHNOLOGIES
To: THOTTATHIL, JOHN K.
Reel/Frame 042630/0620 →
RESCISSION OF ASSIGNMENT Recorded Jan 26, 2017
From: SURMAN, MATTHEW; GOLDEN, KATHRYN; PASETTO, PAOLO; JIN, XIAOMIN; JIANG, XIAOWU; CAMARA, FATOUMATA
To: WATERVILLE VALLEY TECHNOLOGIES, INC.
Reel/Frame 041502/0904 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2017
From: SURMAN, MATTHEW; GOLDEN, KATHRYN; PASETTO, PAOLO; JIN, XIAOMIN; JIANG, XIAOWU; CAMARA, FATOUMATA
To: ALBANY MOLECULAR RESEARCH, INC.
Reel/Frame 041092/0686 →
Continuity (2)
Provisional Application 62153157 · Apr 27, 2015
Related Publication 20160326182A1 · Nov 10, 2016